The market for candidiasis therapeutics was valued at US$ 3109.18 million in 2022 and is anticipated to reach US$ 4275.79 million by 2032, at a CAGR of 3.25 percent.
| Report Attribute | Details |
|---|---|
| Candidiasis Therapeutics Market Value (2022) | US$ 3109.18 Million |
| Candidiasis Therapeutics Market Anticipated Value (2032) | US$ 4275.79 Million |
| Candidiasis Therapeutics Market Growth Rate (2022 to 2032) | 3.25% CAGR |
Due to developments in the field of treating skin infections, there has been an increase in demand for therapies for candidiasis in the global market. The dermatological community is under pressure from the medical community to create new methods for treating skin infections. A skin illness brought on by candida is called candidiasis, sometimes referred to as the common yeast infection. In severe circumstances, it can infiltrate past the mucous membrane and harm the skin's membrane. It is crucial to have a reliable system in place for treating candidiasis in people for this reason. This presents a growth opportunity for market players.
Humans are susceptible to numerous candidiasis infections, including cutaneous candidiasis, vaginal yeast infection, and oral thrush. In the years to come, it is anticipated that the global candidiasis therapeutics market's revenue index will rise.
The severity of candidiasis over the long term has been noted by numerous doctors and dermatologists. The market for treatments for candidiasis has grown recently as a result of this. Another factor that has boosted demand in the global market for candidiasis therapeutics recently is the existence of a rapidly expanding healthcare sector. The development of market vendors is anticipated to be boosted by the existence of a thriving industry for therapeutics against candidiasis.
Candidiasis or commonly known as thrush is a fungal infection affecting men and women of all age groups. When thrush extends into the throat it causes esophagitis. It is also known by other names such as candidosis, moniliasis, and oidiomycosis. The effects of this infection are seen on a dermal, internal and systemic level wherein it is known as candidemia or intestinal thrush.
The market is dynamic due to widespread occurrence of this disease, in particular as recurrent infections, limitations of safe and efficacious antifungals as well as the lack of reliable preventative approaches. The major drug classes for treatment include azoles, polyenes and echinocandins.
• Serious Consequences of Skin Infections
As new lines of therapy for skin infections emerge, the global market for candidiasis treatments is predicted to generate substantial revenues. Additionally, several medical professionals have underlined the need to provide the best care possible for patients with any kind of skin infection. This is because even a small skin infection might endanger a person's general health.
• Developments in the Dermatology Field
Therapeutics for treating candidiasis are expected to provide substantial revenues as dermatology draws new funding. The development of innovative medications for treating skin infections has also been aided by several efforts, which have accelerated the expansion of the worldwide candidiasis therapeutics market. In the coming years, market growth is anticipated to be aided by the increasing public preference for skin care.
Increase in number of patients affected by candidiasis infection, increasing consumer inclination towards maintaining aesthetic appearance and growing awareness for candidiasis infection in developing markets are expected to boost the market growth over the forecast period. This is mainly due to urbanization and rising hygiene awareness in developing countries.
Less R&D activity in this sector and availability of alternative treatments is expected to restraint the candidiasis therapeutics market over the forecast year. The factors such as narrow pipeline molecules and competition from herbal medicines and alternate therapies such as probiotic are expected to restrain the market growth over the forecast period.
The global market for anti-candidiasis agents is expected to grow with a healthy CAGR over the forecast period. The market for systemic candidiasis is driven by increases in the susceptible immune compromised patient pool. Thrush occurs in approximately 2–5 percent of healthy new born and affect them mainly during their first year of life. Over 1 million adult women and adolescent girls in the U. S. develop vaginal yeast infections each year.
Based on geographic regions, gastroesophageal reflux disease therapeutics market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific and Middle East & Africa. The disease is growing globally and is not restricted to any particular region.
North America and Europe region account for the largest markets revenue share due to higher awareness of the disease amongst individuals and also availability of better treatment. Asia-Pacific also offers considerable opportunities owing to low unmet need in this region.
The anti-fungal candidiasis treatment is a highly fragmented mature market with a large number of generics. Major players in the market are Bayer, Teva Pharmaceuticals, Stellar Pharma, Pfizer, Wockhardt, Ranbaxy, Bristol Laboratories, Glenmark Pharmaceuticals, Taro Pharmaceuticals and Perrigo among many other local players.
There are several types of formulations available for treatment based on the modality such as pills, powders, ointments and injectable. In 2013, Astellas Pharma reported positive results from its phase III drug isavuconazole which is one of the only first-in-class molecules expected to enter the market.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Vulvovaginal candidiasis (VVC) is a vaginal fungal infection that has been proven to be brought on by a member of the Candida genus, typically Candida albicans. Other Candida species or yeasts can occasionally be the source of the VVC. Since VVC is a relapsing vaginal fungal infection, it is also known as recurrent vulvovaginal candidiasis (RVVC). The high prevalence of infection among the population is fueling segment growth, and the future is expected to be positive for the vulvovaginal candidiasis market.
Growth in the category is also anticipated to be boosted by more research into the prevalence of VVC or RVVC. According to a study released in August 2021 titled "Treating (Recurrent) Vulvovaginal Candidiasis with Medical-Grade Honey-Concepts and Practical Considerations," the prevalence varies depending on the population's age and can reach as high as 9%. Relapses happen within six months after fluconazole maintenance medication (most often used treatment among other possibilities) in 57% of the cases because there aren't any other options for treatment.
The segment of vulvovaginal candidiasis, therefore, demands additional attention and therapies for treatment due to the high frequency of infection among the target group, thus driving the segment's expansion in the process.
Additionally, more research and development (R&D) is conducted for the segment. The development of products for vaginal yeast infections by major manufacturers is expected to fuel the segment's growth. For instance, Brexafemme (ibrexafungerp) was introduced in the United States in February 2021 thanks to a partnership between SCYNEXIS, Inc., a biotechnology company specializing in the development of therapies and medications for fungal infections, and Amplity Health, one of the world's top contract commercialization organizations.
Additionally, Mycovia Pharmaceutical's brand-new drug VIVJOA (oteseconazole), the first to earn FDA approval, is now the only treatment option for chronic yeast infections or recurrent vulvovaginal candidiasis (RVC). Therefore, it is projected that the segment's growing R&D will fuel expansion. As a result, the aforementioned factors are projected to propel sector growth, which will fuel the anticipated expansion of the market.
Candidiasis market is classified on the basis of route of administration, drug type, anatomy type and distribution channel:
Explore Similar Insights
Candidiasis Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
